No Signs of the DOJ Letting Off the Pedal with Medicare Fraud Investigations
However, a new memo instructs federal prosecutors to ‘avoid overreach’ when parties cooperate with authorities
Keeps You Up-to-Date on Federal & State Laws, Regulations, New Legislation, and Court Cases that Affect Your Diagnostic Lab or Pathology Practice
However, a new memo instructs federal prosecutors to ‘avoid overreach’ when parties cooperate with authorities
CMS recently proposed a rule that would make the False Claims Act rule the standard for overpayments under the Affordable Care Act regulations.
Here’s a quick briefing of the new codes that come into effect on April 1 that your billing staff should know about.
Agency says it will continue to have authority to clear new lab tests and other COVID-19 products on an emergency basis even after the PHE ends.
As we move further into 2023, COVID-19, add-on, and genetic tests will likely remain targets for federal regulators.
Recent fraud case involving phlebotomy company shows why labs need to pay special attention to Medicare specimen collection and travel allowance rules.
A look at the US end-of-emergency game plan and how it will impact lab compliance.
Sales and marketing operations liability risks and the measures labs should and shouldn’t take to manage those risks.
Even though PAMA has slashed reimbursement rates for many tests, overall Medicare Part B spending on lab tests continues to increase.
At the end of 2022, the agency sent a new warning letter to Empowered for unauthorized distribution of COVID-19 test kits.
Case is a recent example of the trend toward Medicare schemes involving telehealth, cancer genetic testing, and kickbacks.